Shintaro Kuroda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shintaro Kuroda has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
- Tsuyoshi Kobayashi
Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health sciences, Hiroshima University, Hiroshima, Japan
20 shared publications - Hideki Ohdan
Department of Gastroenterological and Transplant Surgery Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan
18 shared publications - Masahiro Ohira
Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan
15 shared publications Hideki Ohdan
Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, JPN
13 shared publications- Hiroyuki Tahara
Department of Gastroenterological and Transplant Surgery Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan
12 shared publications Tsuyoshi Kobayashi
Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, JPN
10 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
Safety of Continuing Single‐Agent Antithrombotic Therapy During Emergency Cholecystectomy for Acute Cholecystitis: An Overlap‐Weighted Propensity Score Analysis With the Hiroshima Surgical Study Group of Clinical Oncology ( HiSCO )
Background/Purpose: Optimal perioperative antithrombotic therapy (ATT) management during emergency cholecystectomy for acute cholecystitis remains controversial. We examined whether continuing single‐agent ATT is associated with hemorrhagic risk compared with no ATT. Methods: This retrospective cohort study included 1018 patients (826 without ATT, 192 continued on single‐agent ATT) at seven institutions (2020–2023). Propensity score overlap weighting balanced 12 baseline covariates. The primary outcome was intraoperative blood loss > 100 mL; risk ratios and 95% confidence intervals were estimated via modified Poisson regression, with upper confidence bound compared against a pre‐specified risk ratio (1.5). Results: The primary outcome occurred in 27.3% and 25.4% of the non‐ATT and continued‐ATT groups, respectively (risk ratio: 0.93, 95% confidence interval: 0.69–1.26). The upper bound of the confidence interval was within the pre‐specified margin. No significant differences were observed in perioperative bleeding complications or hospital stay. Secondary outcomes, sensitivity analyses, and drug‐specific subgroup analyses (including direct oral anticoagulants) yielded consistent results. Conclusions: Continuing single‐agent ATT was comparable to no ATT regarding bleeding during cholecystectomy for acute cholecystitis. These findings suggest that emergency cholecystectomy can be performed without meaningful increases in hemorrhagic risk in patients for whom adequate preoperative ATT washout is not feasible.
- 5 November 2026
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
Open AccessSafety of Continuing Single‐Agent Antithrombotic Therapy During Emergency Cholecystectomy for Acute Cholecystitis: An Overlap‐Weighted Propensity Score Analysis With the Hiroshima Surgical Study Group of Clinical Oncology ( HiSCO )
Background/Purpose: Optimal perioperative antithrombotic therapy (ATT) management during emergency cholecystectomy for acute cholecystitis remains controversial. We examined whether continuing single‐agent ATT is associated with hemorrhagic risk compared with no ATT. Methods: This retrospective cohort study included 1018 patients (826 without ATT, 192 continued on single‐agent ATT) at seven institutions (2020–2023). Propensity score overlap weighting balanced 12 baseline covariates. The primary outcome was intraoperative blood loss > 100 mL; risk ratios and 95% confidence intervals were estimated via modified Poisson regression, with upper confidence bound compared against a pre‐specified risk ratio (1.5). Results: The primary outcome occurred in 27.3% and 25.4% of the non‐ATT and continued‐ATT groups, respectively (risk ratio: 0.93, 95% confidence interval: 0.69–1.26). The upper bound of the confidence interval was within the pre‐specified margin. No significant differences were observed in perioperative bleeding complications or hospital stay. Secondary outcomes, sensitivity analyses, and drug‐specific subgroup analyses (including direct oral anticoagulants) yielded consistent results. Conclusions: Continuing single‐agent ATT was comparable to no ATT regarding bleeding during cholecystectomy for acute cholecystitis. These findings suggest that emergency cholecystectomy can be performed without meaningful increases in hemorrhagic risk in patients for whom adequate preoperative ATT washout is not feasible.
- Open Access
- 12 August 2026
- Published by Wolters Kluwer Health in International Journal of Surgery Protocols
A protocol for a prospective single-arm feasibility study of preoperative home-based hydrogen gas inhalation in liver surgery
Introduction: Hydrogen therapy has been reported to exert antioxidative and anti-inflammatory effects and has attracted increasing clinical interest across various medical fields. In cancer treatment, a waiting period often exists between the treatment decision and surgery; however, structured and evidence-based preoperative interventions during this interval remain limited. Home-based hydrogen gas inhalation, which enables long-duration, repeated administration, may represent a feasible and practical strategy for preoperative optimization. This study aims to evaluate the safety and feasibility of a standardized home-based hydrogen gas inhalation protocol in patients scheduled for liver resection. Methods: This is a prospective, single-center, single-arm, open-label exploratory clinical trial with a planned enrollment of eight participants. Eligible patients scheduled for liver resection will undergo home-based hydrogen gas inhalation during sleep and, additionally, for approximately 1 hour each morning and evening for 14 consecutive days in the preoperative waiting period. The primary endpoint is feasibility, defined as protocol adherence based on predefined inhalation duration criteria. Safety will be assessed by the incidence of adverse events. Secondary and exploratory assessments include changes in inflammation-related, immune-related, and nutrition-related indices, oxidative stress markers, body composition parameters, questionnaire-based quality of life, and tumor markers. This study is registered in the Japan Registry of Clinical Trials (jRCT: jRCTs062250073). Conclusion: This study protocol is designed to evaluate the feasibility and safety of preoperative home-based hydrogen gas inhalation and to generate preliminary data to inform the design of subsequent clinical trials investigating its potential role in perioperative care for liver surgery.
- 12 August 2026
- Published by Wolters Kluwer Health in International Journal of Surgery Protocols
Open AccessA protocol for a prospective single-arm feasibility study of preoperative home-based hydrogen gas inhalation in liver surgery
Introduction: Hydrogen therapy has been reported to exert antioxidative and anti-inflammatory effects and has attracted increasing clinical interest across various medical fields. In cancer treatment, a waiting period often exists between the treatment decision and surgery; however, structured and evidence-based preoperative interventions during this interval remain limited. Home-based hydrogen gas inhalation, which enables long-duration, repeated administration, may represent a feasible and practical strategy for preoperative optimization. This study aims to evaluate the safety and feasibility of a standardized home-based hydrogen gas inhalation protocol in patients scheduled for liver resection. Methods: This is a prospective, single-center, single-arm, open-label exploratory clinical trial with a planned enrollment of eight participants. Eligible patients scheduled for liver resection will undergo home-based hydrogen gas inhalation during sleep and, additionally, for approximately 1 hour each morning and evening for 14 consecutive days in the preoperative waiting period. The primary endpoint is feasibility, defined as protocol adherence based on predefined inhalation duration criteria. Safety will be assessed by the incidence of adverse events. Secondary and exploratory assessments include changes in inflammation-related, immune-related, and nutrition-related indices, oxidative stress markers, body composition parameters, questionnaire-based quality of life, and tumor markers. This study is registered in the Japan Registry of Clinical Trials (jRCT: jRCTs062250073). Conclusion: This study protocol is designed to evaluate the feasibility and safety of preoperative home-based hydrogen gas inhalation and to generate preliminary data to inform the design of subsequent clinical trials investigating its potential role in perioperative care for liver surgery.
- Open Access
- 21 July 2026
- Published by Wiley in Hepatology Research
- Vol. 56 (10) , 1556-1561
Hepatic Carcinoma With Epithelial–Myoepithelial Differentiation and Metachronous Intrahepatic Recurrence Following Curative Resection: A Rare Case Report
Background and Aim: Epithelial‐myoepithelial carcinoma (EMC), a malignant tumor with biphasic epithelial and myoepithelial differentiation, is typically a salivary gland neoplasm. Contrastingly, myoepithelial carcinoma (MEC) predominantly comprises myoepithelial cells. In salivary gland pathology, biphasic ductal tumors are classified as EMC, even with a predominant myoepithelial component. Primary hepatic tumors showing myoepithelial and epithelial–myoepithelial differentiation are rare, with uncertain definition and clinical behavior owing to limited reported hepatic carcinoma with MEC/EMC spectrum cases. Here, we report a unique case with intrahepatic recurrence that was successfully managed with repeat hepatectomies. Case: A 66‐year‐old woman presented with pain in the right hypochondrium. Imaging revealed a 13 cm tumor in the right hepatic lobe, and biopsy suggested squamous cell carcinoma. After portal vein embolization, right trisectionectomy was performed. Histopathology revealed a biphasic structure with duct‐forming epithelial cells surrounded by myoepithelial cells, confirming hepatic carcinoma with epithelial–myoepithelial differentiation. After 2 years, multiple intrahepatic recurrences without extrahepatic disease were detected and repeat hepatectomies were performed. The patient remains recurrence‐free 1 year post‐reoperation. Conclusions: Hepatic carcinoma with epithelial–myoepithelial differentiation is rare, with uncertain definition and clinical behavior. Careful exclusion of extrahepatic primaries, detailed immunophenotyping, and long‐term surveillance are essential. Repeat hepatectomies may be a curative option for intrahepatic recurrence in selected patients.
- 21 July 2026
- Published by Wiley in Hepatology Research
- Vol. 56 (10) , 1556-1561
Open AccessHepatic Carcinoma With Epithelial–Myoepithelial Differentiation and Metachronous Intrahepatic Recurrence Following Curative Resection: A Rare Case Report
Background and Aim: Epithelial‐myoepithelial carcinoma (EMC), a malignant tumor with biphasic epithelial and myoepithelial differentiation, is typically a salivary gland neoplasm. Contrastingly, myoepithelial carcinoma (MEC) predominantly comprises myoepithelial cells. In salivary gland pathology, biphasic ductal tumors are classified as EMC, even with a predominant myoepithelial component. Primary hepatic tumors showing myoepithelial and epithelial–myoepithelial differentiation are rare, with uncertain definition and clinical behavior owing to limited reported hepatic carcinoma with MEC/EMC spectrum cases. Here, we report a unique case with intrahepatic recurrence that was successfully managed with repeat hepatectomies. Case: A 66‐year‐old woman presented with pain in the right hypochondrium. Imaging revealed a 13 cm tumor in the right hepatic lobe, and biopsy suggested squamous cell carcinoma. After portal vein embolization, right trisectionectomy was performed. Histopathology revealed a biphasic structure with duct‐forming epithelial cells surrounded by myoepithelial cells, confirming hepatic carcinoma with epithelial–myoepithelial differentiation. After 2 years, multiple intrahepatic recurrences without extrahepatic disease were detected and repeat hepatectomies were performed. The patient remains recurrence‐free 1 year post‐reoperation. Conclusions: Hepatic carcinoma with epithelial–myoepithelial differentiation is rare, with uncertain definition and clinical behavior. Careful exclusion of extrahepatic primaries, detailed immunophenotyping, and long‐term surveillance are essential. Repeat hepatectomies may be a curative option for intrahepatic recurrence in selected patients.
- 1 February 2025
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 112 (2)
Impact of pre-compression versus non-compression before parenchyma transection in left-sided pancreatic resection on the rate of clinically relevant pancreatic fistula: multicentre randomized clinical trial
Background: Previous retrospective studies have demonstrated the effectiveness of parenchymal pre-compression in reducing pancreatic fistula after left-sided pancreatic resection; however, no multicentre RCT has been conducted. The aim of this study was to investigate whether pre-compression reduces grade B/C pancreatic fistula after left-sided pancreatic resection. Methods: Between 23 March 2021 and 26 January 2023, patients scheduled for left-sided pancreatic resection were enrolled in a multicentre RCT at 13 hospitals in Japan. These patients were randomly assigned (1 : 1) to the pre-compression group or the non-compression group. The primary endpoint was the incidence of grade B/C pancreatic fistula and the secondary endpoint was it in the subgroup. Results: Overall, 180 patients were assigned to the pre-compression group and the non-compression group (92 patients and 88 patients respectively) and 171 patients were analysed (88 patients in the pre-compression group and 83 patients in the non-compression group). Grade B/C pancreatic fistula was observed in 22 patients (12.9%), including 11 of 88 patients (12.5%) in the pre-compression group and 11 of 83 patients (13.3%) in the non-compression group (OR 0.94 (95% c.i. 0.38 to 2.31); P = 0.883). Conclusion: A statistically significant difference in the incidence of grade B/C pancreatic fistula was not observed between the pre-compression group and the non-compression group. Registration number: UMIN000042700 (https://www.umin.ac.jp).
- 1 February 2025
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 112 (2)
Impact of pre-compression versus non-compression before parenchyma transection in left-sided pancreatic resection on the rate of clinically relevant pancreatic fistula: multicentre randomized clinical trial
Background: Previous retrospective studies have demonstrated the effectiveness of parenchymal pre-compression in reducing pancreatic fistula after left-sided pancreatic resection; however, no multicentre RCT has been conducted. The aim of this study was to investigate whether pre-compression reduces grade B/C pancreatic fistula after left-sided pancreatic resection. Methods: Between 23 March 2021 and 26 January 2023, patients scheduled for left-sided pancreatic resection were enrolled in a multicentre RCT at 13 hospitals in Japan. These patients were randomly assigned (1 : 1) to the pre-compression group or the non-compression group. The primary endpoint was the incidence of grade B/C pancreatic fistula and the secondary endpoint was it in the subgroup. Results: Overall, 180 patients were assigned to the pre-compression group and the non-compression group (92 patients and 88 patients respectively) and 171 patients were analysed (88 patients in the pre-compression group and 83 patients in the non-compression group). Grade B/C pancreatic fistula was observed in 22 patients (12.9%), including 11 of 88 patients (12.5%) in the pre-compression group and 11 of 83 patients (13.3%) in the non-compression group (OR 0.94 (95% c.i. 0.38 to 2.31); P = 0.883). Conclusion: A statistically significant difference in the incidence of grade B/C pancreatic fistula was not observed between the pre-compression group and the non-compression group. Registration number: UMIN000042700 (https://www.umin.ac.jp).
- Open Access
- 28 June 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (6) , e0306307
Feasibility, safety, and efficacy of intraoperative magnetic resonance imaging-guided hepatectomy for small hepatocellular carcinoma: A retrospective study
Advancements in diagnostic modalities, such as enhanced magnetic resonance imaging, provide increased opportunities for identifying small hepatocellular carcinoma that is undetectable on preoperative ultrasonography. Whether it is acceptable to leave these lesions untreated is uncertain. This study aimed to evaluate the safety and efficacy of intraoperative magnetic resonance imaging-guided hepatectomy using new navigation systems. This study was conducted between July 2019 and January 2023. We retrospectively studied the clinicopathological features and prognoses of patients with small hepatocellular carcinoma who underwent curative intraoperative magnetic resonance imaging-guided hepatectomy. We evaluated 23 patients (median age, 75 years), among whom 20 (87.0%) were males. Seven (30.4%) and 15 (65.2%) patients had liver cirrhosis and a history of hepatectomy, respectively. The median size of the target lesions was 9 mm, with a median distance of 6 mm from the liver surface. Despite being undetectable preoperatively on contrast-enhanced ultrasonography, all lesions were identified using intraoperative magnetic resonance imaging. Based on pathological findings, 76.0% of the lesions were malignant. The complete resection rate was 100%, and tumor-free margins were confirmed in 96.0% of the patients. Intraoperative magnetic resonance imaging-guided hepatectomy is safe and effective in identifying and resecting small hepatocellular carcinoma lesions that are undetectable on preoperative ultrasonography.
- 28 June 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (6) , e0306307
Open AccessFeasibility, safety, and efficacy of intraoperative magnetic resonance imaging-guided hepatectomy for small hepatocellular carcinoma: A retrospective study
Advancements in diagnostic modalities, such as enhanced magnetic resonance imaging, provide increased opportunities for identifying small hepatocellular carcinoma that is undetectable on preoperative ultrasonography. Whether it is acceptable to leave these lesions untreated is uncertain. This study aimed to evaluate the safety and efficacy of intraoperative magnetic resonance imaging-guided hepatectomy using new navigation systems. This study was conducted between July 2019 and January 2023. We retrospectively studied the clinicopathological features and prognoses of patients with small hepatocellular carcinoma who underwent curative intraoperative magnetic resonance imaging-guided hepatectomy. We evaluated 23 patients (median age, 75 years), among whom 20 (87.0%) were males. Seven (30.4%) and 15 (65.2%) patients had liver cirrhosis and a history of hepatectomy, respectively. The median size of the target lesions was 9 mm, with a median distance of 6 mm from the liver surface. Despite being undetectable preoperatively on contrast-enhanced ultrasonography, all lesions were identified using intraoperative magnetic resonance imaging. Based on pathological findings, 76.0% of the lesions were malignant. The complete resection rate was 100%, and tumor-free margins were confirmed in 96.0% of the patients. Intraoperative magnetic resonance imaging-guided hepatectomy is safe and effective in identifying and resecting small hepatocellular carcinoma lesions that are undetectable on preoperative ultrasonography.
- Open Access
- 15 December 2023
- Published by Wolters Kluwer Health in International Journal of Surgery Protocols
- Vol. 28 (1) , 1-5
Protocol to evaluate the efficacy and safety of tolvaptan in patients with refractory ascites after liver resection: an open-label, single-arm phase I/II study
Background: In patients with chronic liver diseases such as cirrhosis, massive ascites after hepatic resection is the cause of prolonged hospitalization and worsening prognosis. Recently, the efficacy of tolvaptan in refractory ascites has been reported; however, there are no reports on the efficacy or safety of tolvaptan for refractory ascites after hepatic resection. This study aims to evaluate the efficacy of early administration of tolvaptan in patients with refractory ascites after hepatic resection. Materials and methods: This is an open-label, single-arm phase I/II study. This study subject will comprise patients scheduled for hepatic resection of a liver tumor. Patients with refractory ascites after hepatic resection (drainage volume on postoperative day 1 ≥5 ml/body weight 1 kg/day) will be treated with tolvaptan. The primary endpoint will include the maximum change in body weight after hepatic resection relative to the preoperative baseline. The secondary endpoints will include drainage volume, abdominal circumference, urine output, postoperative complication rate (heart failure and respiratory failure), number of days required for postoperative weight gain because of ascites to decrease to preoperative weight, change in improvement of postoperative pleural effusion, total amount of albumin or fresh frozen plasma transfusion, type and amount of diuretics used, and postoperative hospitalization days. Conclusion: This trial will evaluate the efficacy and safety of tolvaptan prophylaxis for refractory ascites after hepatic resection. As there are no reports demonstrating the efficacy of tolvaptan prophylaxis for refractory ascites after hepatic resection, the authors expect that these findings will lead to future phase III trials and provide valuable indications for the selection of treatments for refractory postoperative ascites.
- 15 December 2023
- Published by Wolters Kluwer Health in International Journal of Surgery Protocols
- Vol. 28 (1) , 1-5
Open AccessProtocol to evaluate the efficacy and safety of tolvaptan in patients with refractory ascites after liver resection: an open-label, single-arm phase I/II study
Background: In patients with chronic liver diseases such as cirrhosis, massive ascites after hepatic resection is the cause of prolonged hospitalization and worsening prognosis. Recently, the efficacy of tolvaptan in refractory ascites has been reported; however, there are no reports on the efficacy or safety of tolvaptan for refractory ascites after hepatic resection. This study aims to evaluate the efficacy of early administration of tolvaptan in patients with refractory ascites after hepatic resection. Materials and methods: This is an open-label, single-arm phase I/II study. This study subject will comprise patients scheduled for hepatic resection of a liver tumor. Patients with refractory ascites after hepatic resection (drainage volume on postoperative day 1 ≥5 ml/body weight 1 kg/day) will be treated with tolvaptan. The primary endpoint will include the maximum change in body weight after hepatic resection relative to the preoperative baseline. The secondary endpoints will include drainage volume, abdominal circumference, urine output, postoperative complication rate (heart failure and respiratory failure), number of days required for postoperative weight gain because of ascites to decrease to preoperative weight, change in improvement of postoperative pleural effusion, total amount of albumin or fresh frozen plasma transfusion, type and amount of diuretics used, and postoperative hospitalization days. Conclusion: This trial will evaluate the efficacy and safety of tolvaptan prophylaxis for refractory ascites after hepatic resection. As there are no reports demonstrating the efficacy of tolvaptan prophylaxis for refractory ascites after hepatic resection, the authors expect that these findings will lead to future phase III trials and provide valuable indications for the selection of treatments for refractory postoperative ascites.
- Open Access
- 15 December 2023
- Published by Springer Nature in Cureus
- Vol. 15 (12) , e50603
Prospective Exploratory Phase I Clinical Trial Assessing the Safety of Preoperative Marking for Small Liver Tumors
Background Small tumors in liver cirrhosis are difficult to distinguish using intraoperative ultrasonography. In addition, preoperative chemotherapy for metastatic liver cancer may diminish tumor size, thus making tumors difficult to identify intraoperatively. To address such difficulties, we devised a method to mark liver tumors preoperatively to facilitate intraoperative identification. This study aimed to investigate the safety of a preoperative liver tumor marking method. Methodology This exploratory prospective clinical trial included patients with liver tumors measuring ≤20 mm requiring resection. Preoperative marking was performed by placing a coil for embolization of blood vessels near the tumor using either the transcatheter or percutaneous approach. The tumor was identified and resected by intraoperative ultrasonography based on the marker. The study was registered in the University Hospital Medical Information Network Clinical Trials Registry (UMIN000028608). Results Overall, 19 patients (9 with primary liver cancer and 10 with metastatic tumors) were recruited. The transcatheter and percutaneous methods were used in 13 and 6 patients, respectively. Marking was not possible in two patients in the transcatheter group because the catheter could not be guided to the vicinity of the tumor. There were no marking-related complications. Hepatectomy was performed in all but one patient who was not fit for hepatectomy owing to the development of a metastatic liver tumor. The markers were adequately identified during hepatectomy. Additionally, there were no difficulties in the surgical procedure or postoperative complications. Conclusions Preoperative marking with embolization coils can be performed safely for intraoperative identification of liver nodules.
- 15 December 2023
- Published by Springer Nature in Cureus
- Vol. 15 (12) , e50603
Open AccessProspective Exploratory Phase I Clinical Trial Assessing the Safety of Preoperative Marking for Small Liver Tumors
Background Small tumors in liver cirrhosis are difficult to distinguish using intraoperative ultrasonography. In addition, preoperative chemotherapy for metastatic liver cancer may diminish tumor size, thus making tumors difficult to identify intraoperatively. To address such difficulties, we devised a method to mark liver tumors preoperatively to facilitate intraoperative identification. This study aimed to investigate the safety of a preoperative liver tumor marking method. Methodology This exploratory prospective clinical trial included patients with liver tumors measuring ≤20 mm requiring resection. Preoperative marking was performed by placing a coil for embolization of blood vessels near the tumor using either the transcatheter or percutaneous approach. The tumor was identified and resected by intraoperative ultrasonography based on the marker. The study was registered in the University Hospital Medical Information Network Clinical Trials Registry (UMIN000028608). Results Overall, 19 patients (9 with primary liver cancer and 10 with metastatic tumors) were recruited. The transcatheter and percutaneous methods were used in 13 and 6 patients, respectively. Marking was not possible in two patients in the transcatheter group because the catheter could not be guided to the vicinity of the tumor. There were no marking-related complications. Hepatectomy was performed in all but one patient who was not fit for hepatectomy owing to the development of a metastatic liver tumor. The markers were adequately identified during hepatectomy. Additionally, there were no difficulties in the surgical procedure or postoperative complications. Conclusions Preoperative marking with embolization coils can be performed safely for intraoperative identification of liver nodules.
- Open Access
- 18 November 2023
- Published by Springer Nature in Cureus
- Vol. 15 (11) , e49028
A Multicenter, Open-Label, Single-Arm Phase I Trial of Dual-Wield Parenchymal Transection: A New Technique of Liver Resection Using the Cavitron Ultrasonic Surgical Aspirator and Water-Jet Scalpel Simultaneously (HiSCO-14 Trial)
Purpose: This study evaluated the safety and feasibility of a technique of liver resection named dual-wield parenchymal transection technique (DWT), using cavitron ultrasonic surgical aspirator (CUSA) and water-jet scalpel simultaneously. Methods: This multicenter, prospective, open-label, and single-arm phase I trial included patients aged 20 years or older with hepatic tumors indicated for surgical resection and scheduled for open radical resection. This study was conducted at two institutions affiliated with the Hiroshima Surgical Study Group of Clinical Oncology (HiSCO). The primary endpoint was the proportion of massive intraoperative blood loss (≥ 1000 mL). The secondary endpoints were the amount of blood loss, operative time, parenchymal transection speed, postoperative complications, and mortality. The safety endpoints were device failure and adverse events associated with devices. Results: From June 2022 to May 2023, 20 patients were enrolled; one was excluded and 19 were included in the full analysis set (FAS). In the FAS, segmentectomy was performed in nine cases, sectionectomy in four cases, and hemihepatectomy in six cases. Radical resection was achieved in all patients. Intraoperative blood loss greater than 1000 mL was observed in five patients (26.3%). The median amount of blood loss was 545 mL (range, 180-4413), and blood transfusions were performed on two patients (10.5%). The median operative time was 346 minutes (range, 238-543) and the median parenchymal transection speed was 1.2 cm2/minute (range, 0.5-5.1). Postoperative complications of Clavien-Dindo classification ≥ Grade 3 occurred in four patients (21.1%). No mortalities occurred in this study. In the safety analysis, there were no device failures or adverse events associated with devices. Conclusions: This study demonstrated the safety and feasibility of DWT for liver resection. The efficacy of the DWT will be evaluated in future clinical trials.
- 18 November 2023
- Published by Springer Nature in Cureus
- Vol. 15 (11) , e49028
Open AccessA Multicenter, Open-Label, Single-Arm Phase I Trial of Dual-Wield Parenchymal Transection: A New Technique of Liver Resection Using the Cavitron Ultrasonic Surgical Aspirator and Water-Jet Scalpel Simultaneously (HiSCO-14 Trial)
Purpose: This study evaluated the safety and feasibility of a technique of liver resection named dual-wield parenchymal transection technique (DWT), using cavitron ultrasonic surgical aspirator (CUSA) and water-jet scalpel simultaneously. Methods: This multicenter, prospective, open-label, and single-arm phase I trial included patients aged 20 years or older with hepatic tumors indicated for surgical resection and scheduled for open radical resection. This study was conducted at two institutions affiliated with the Hiroshima Surgical Study Group of Clinical Oncology (HiSCO). The primary endpoint was the proportion of massive intraoperative blood loss (≥ 1000 mL). The secondary endpoints were the amount of blood loss, operative time, parenchymal transection speed, postoperative complications, and mortality. The safety endpoints were device failure and adverse events associated with devices. Results: From June 2022 to May 2023, 20 patients were enrolled; one was excluded and 19 were included in the full analysis set (FAS). In the FAS, segmentectomy was performed in nine cases, sectionectomy in four cases, and hemihepatectomy in six cases. Radical resection was achieved in all patients. Intraoperative blood loss greater than 1000 mL was observed in five patients (26.3%). The median amount of blood loss was 545 mL (range, 180-4413), and blood transfusions were performed on two patients (10.5%). The median operative time was 346 minutes (range, 238-543) and the median parenchymal transection speed was 1.2 cm2/minute (range, 0.5-5.1). Postoperative complications of Clavien-Dindo classification ≥ Grade 3 occurred in four patients (21.1%). No mortalities occurred in this study. In the safety analysis, there were no device failures or adverse events associated with devices. Conclusions: This study demonstrated the safety and feasibility of DWT for liver resection. The efficacy of the DWT will be evaluated in future clinical trials.
- Open Access
Preoperative percutaneous or transvascular marking for curative resection of small liver tumours with potential for missing during hepatectomy: a study protocol for an open-label, single-arm phase II study
Introduction Small liver tumours are difficult to identify during hepatectomy, which prevents curative tumour excision. Preoperative marking is a standard practice for small, deep-seated tumours in other solid organs; however, its effectiveness for liver tumours has not been validated. The objective of this study is to evaluate the effectiveness of preoperative markings for curative resection of small liver tumours. Methods and analysis This is an open-label, single-arm, single-centre, phase II study. Patients with liver tumours of ≤15 mm requiring hepatectomy will be enrolled and will undergo preoperative marking by placing a microcoil near the tumour using either the percutaneous or transvascular approach. The tumours, including the indwelling markers, will be excised. The primary endpoint will be the successful resection rate of liver tumours, defined as achieving a surgical margin of ≥5 mm and ≤15 mm. Secondary endpoints will include the results of preoperative marking and hepatectomy. Ethics and dissemination Ethical approval for this trial was obtained from the Ethical Committee for Clinical Research of Hiroshima University, Japan. The results will be published at an academic conference or by submitting a paper to a peer-reviewed journal. Trial registration number jRCTs062220088.
Open AccessPreoperative percutaneous or transvascular marking for curative resection of small liver tumours with potential for missing during hepatectomy: a study protocol for an open-label, single-arm phase II study
Introduction Small liver tumours are difficult to identify during hepatectomy, which prevents curative tumour excision. Preoperative marking is a standard practice for small, deep-seated tumours in other solid organs; however, its effectiveness for liver tumours has not been validated. The objective of this study is to evaluate the effectiveness of preoperative markings for curative resection of small liver tumours. Methods and analysis This is an open-label, single-arm, single-centre, phase II study. Patients with liver tumours of ≤15 mm requiring hepatectomy will be enrolled and will undergo preoperative marking by placing a microcoil near the tumour using either the percutaneous or transvascular approach. The tumours, including the indwelling markers, will be excised. The primary endpoint will be the successful resection rate of liver tumours, defined as achieving a surgical margin of ≥5 mm and ≤15 mm. Secondary endpoints will include the results of preoperative marking and hepatectomy. Ethics and dissemination Ethical approval for this trial was obtained from the Ethical Committee for Clinical Research of Hiroshima University, Japan. The results will be published at an academic conference or by submitting a paper to a peer-reviewed journal. Trial registration number jRCTs062220088.
- Open Access
- 7 June 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (10) , 2392-2400
Adoptive immunotherapy overcomes genetic susceptibility to bloodstream infections due to fc-gamma receptor polymorphisms after liver transplantation
- 7 June 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (10) , 2392-2400
Open AccessAdoptive immunotherapy overcomes genetic susceptibility to bloodstream infections due to fc-gamma receptor polymorphisms after liver transplantation